Truist Securities Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $7-Report Released on 7th Nov
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Gregory Fraser has maintained a 'Buy' rating on Amneal Pharmaceuticals (NYSE:AMRX) and raised the price target from $6 to $7.
November 08, 2023 | 3:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amneal Pharmaceuticals' price target has been raised from $6 to $7 by Truist Securities, which maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by Truist Securities indicates a positive outlook for Amneal Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100